Trials / Completed
CompletedNCT00708006
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGS1029 | Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2011-12-01
- Completion
- 2012-01-01
- First posted
- 2008-07-02
- Last updated
- 2013-11-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00708006. Inclusion in this directory is not an endorsement.